The Effect of Rosuvastatin on Adenosine Metabolism

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-11-30

Study Completion Date

2008-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to show whether rosuvastatin influences adenosine metabolism. Therefore we will determine whether rosuvasatin increases dipyridamole-induced vasodilation by increased adenosine receptor stimulation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Is Augmentation of PORH by Rosuvastatin Adenosine-receptor Mediated?

NCT00851175

Atherosclerosis Cardiovascular Disease

COMPLETED PHASE4

Rosuvastatin and Ischemia Reperfusion

NCT00315510

Ischemia

COMPLETED PHASE2

A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID)

NCT00240318

Coronary Arteriosclerosis

COMPLETED PHASE3

Study of PF-04965842 Effect on Rosuvastatin Pharmacokinetics in Healthy Participants

NCT03806101

Healthy

COMPLETED PHASE1

A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-132577 Can Affect Rosuvastatin's Fate in the Body (Amount and Time of Presence in the Blood)

NCT03245229

Healthy Subjects

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adenosine Metabolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

1 dd for 7-10 days

2

Group Type EXPERIMENTAL

rosuvastatin

Intervention Type DRUG

1 dd 20 mg for 7-10 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

placebo

1 dd for 7-10 days

Intervention Type DRUG

rosuvastatin

1 dd 20 mg for 7-10 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age 18 - 50 years
* Signed informed consent

Exclusion Criteria

* hypertension
* hypercholesterolemia
* diabetes Mellitus
* alanine aminotransferase \> 90 U/L
* creatinine Kinase \> 440 U/L
* cardiovascular disease
* GFR \< 80 ml/min

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes